K
K. Le Malicot
Researcher at University of Burgundy
Publications - 19
Citations - 303
K. Le Malicot is an academic researcher from University of Burgundy. The author has contributed to research in topics: FOLFOX & Colorectal cancer. The author has an hindex of 6, co-authored 19 publications receiving 231 citations. Previous affiliations of K. Le Malicot include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Prognostic value of KRAS mutations in stage III colon cancer: post-hoc analysis of the PETACC8 phase III trial dataset
Hélène Blons,Hélène Blons,J.F. Emile,K. Le Malicot,C. Julié,Aziz Zaanan,Josep Tabernero,Enrico Mini,Gunnar Folprecht,J.-L. Van Laethem,J. Thaler,John Bridgewater,L. Nørgård-Petersen,E. Van Cutsem,Côme Lepage,M.A. Zawadi,Ramon Salazar,Pierre Laurent-Puig,Pierre Laurent-Puig,Julien Taieb +19 more
TL;DR: KRAS exon 2 mutations are independent predictors of shorter TTR in patients with resected stage III distal colon cancers receiving adjuvant therapy, and future clinical trials in the adjUvant setting should consider both the tumor location and KRAS mutations as important stratification factors.
Journal ArticleDOI
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Thomas Walter,David Tougeron,Eric Baudin,K. Le Malicot,Thierry Lecomte,David Malka,Olivia Hentic,Sylvain Manfredi,I. Bonnet,Rosine Guimbaud,Romain Coriat,Céline Lepère,C. Desauw,Anne Thirot-Bidault,Laetitia Dahan,G. Roquin,Thomas Aparicio,Jean-Louis Legoux,Catherine Lombard-Bohas,Jean-Yves Scoazec,Côme Lepage,Guillaume Cadiot,Laetitia Stephanie,Ivan Borbath,Castex,Caroline Petorin,Eric Terrebonne,Karine Bouhier-Leporrier,Etienne Suc,Vincent Hautefeuille,Vincent Bourgeois,Laurent Cany,François Dewaele,Patricia Niccoli,Jean-François Seitz,Cedric Lecaille,C. Rebischung,Valérie Rossi,Mathieu Baconnier,Olivier Dubreuil,Marc Ferec,Gael Deplanque,Guillaume Geslin,Isabelle Wanicki Caron,Sandrine Lavau denes,Laurent Bedenne,Catherine Ligeza,Eric Maringe,Anne-Laure Ran-Royo,Joël Guigay,Philippe Rougier +50 more
TL;DR: A large prospective series of GEP-NEC showed the predominance of large cell type and advanced stage at diagnosis, mainly impacted by PS and tumour burden, which was found more homogeneous than previously reported.
Journal ArticleDOI
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients
Julien Taieb,Ralyath Balogoun,K. Le Malicot,Josep Tabernero,Enrico Mini,Gunnar Folprecht,J.-L. Van Laethem,J.F. Emile,Claire Mulot,S. Fratte,C.-B. Levaché,L. Saban-Roche,J. Thaler,L.N. Petersen,John Bridgewater,Géraldine Perkins,Côme Lepage,E. Van Cutsem,Aziz Zaanan,Pierre Laurent-Puig +19 more
TL;DR: Though not significant, the clinically relevant 0.76 adjusted HR observed for DFS in favour of adding cetuximab to FOLFOX, in full RAS and BRAF WT stage III colon cancer pts, may justify a new randomized controlled trial testing EGFR inhibitors in this setting.
Journal ArticleDOI
ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
Pierre Laurent-Puig,Ralyath Balogoun,Anne Cayre,K. Le Malicot,J. Tabernero,Enrico Mini,G. Folprecht,J-L. van Laethem,J. Thaler,L. Nørgård Petersen,Eduardo Sánchez,John Bridgewater,S. Ellis,Christophe Locher,C. Lagorce,J-F. Ramé,Côme Lepage,Frédérique Penault-Llorca,Julien Taieb +18 more
Journal ArticleDOI
Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8
Pierre Laurent-Puig,Laetitia Marisa,Mira Ayadi,Yuna Blum,Ralyath Balogoun,Camilla Pilati,K. Le Malicot,Côme Lepage,J.F. Emile,R. Salazar,Daniela Aust,Alex Duval,Janick Selves,Dominique Guenot,Gérard Milano,J.F. Seitz,Julien Taieb,Valérie Boige,A. de Reyniès +18 more